Values as of: 2024-10-30
COMMON STOCK | Medical Devices |
Last Closing
USD 47.1Change
-2.08 (-4.23)%Market Cap
USD 2.57BVolume
0.91MAnalyst Target
USD 64.75Verdict
Verdict
Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
Company Website : https://www.inarimedical.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| DXCM | DexCom Inc |
-0.44 (-0.61%) |
USD 29.04B |
| PODD | Insulet Corporation |
-1.79 (-0.77%) |
USD 16.66B |
| BRKR | Bruker Corporation |
+0.46 (+0.79%) |
USD 9.04B |
| MASI | Masimo Corporation |
+1.84 (+1.30%) |
USD 7.53B |
| TMDX | TransMedics Group Inc |
-6.58 (-7.44%) |
USD 4.17B |
| AXNX | Axonics Modulation Technologie.. |
+0.05 (+0.07%) |
USD 3.59B |
| PRCT | Procept Biorobotics Corp |
-3.66 (-3.79%) |
USD 3.50B |
| LIVN | LivaNova PLC |
-1.63 (-3.08%) |
USD 2.90B |
| QDEL | Quidel Corporation |
+0.62 (+1.62%) |
USD 2.67B |
| IRTC | iRhythm Technologies Inc |
-1.23 (-1.60%) |
USD 2.36B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| WELP:LSE | HAN-GINS Indxx Healthcare.. | 1.13 % | 0.00 % |
-2.65 (-0.48%) |
N/A |
| WELL:LSE | Hanetf Icav - Han-Gins He.. | 0.00 % | 0.00 % |
-0.03 (-0.48%) |
N/A |
| Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -27.45% | 33% | F | 26% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -27.45% | 33% | F | 27% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -23.30% | 29% | F | 24% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -23.30% | 29% | F | 25% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -7.18% | 33% | F | 25% | F | ||
| Dividend Return | -7.18% | 33% | F | 25% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 26.05% | 92% | A | 68% | D+ | ||
| Risk Adjusted Return | -27.58% | 29% | F | 22% | F | ||
| Market Capitalization | 2.57B | 92% | A | 82% | B | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
